420 with CNW — Supreme Court Gives Florida AG Extra Fortnight to File Cannabis Challenge

420 with CNW — Supreme Court Gives Florida AG Extra Fortnight to File Cannabis Challenge

image

The Florida attorney general has received two extra weeks to come up with a brief challenging the addition of a proposed cannabis legalization measure to the 2024 ballot. State Attorney General Ashley Moody’s office originally had until June 5, 2022, to provide the briefs, but it filed a motion to push the deadline. The office stated that it had limited staff and was currently dealing with multiple deadlines that made it unable to meet last Monday’s deadline for the cannabis ballot initiative challenge.

The court motion met no challenges from the cannabis ballot campaign’s lawyers, and the state Supreme Court granted the attorney general’s office a fortnight to complete the briefs. However, the court cautioned the attorney general against seeking further extensions and noted that without any extenuating circumstances, the court may deny further requests for delays.

A week ago, Florida state officials announced that the Smart & Safe Florida campaign that is behind the ballot initiative had gathered enough valid signatures to qualify the measure for next year’s ballot. In fact, the Florida Division of Elections reported that the campaign had collected 967,528 verified signatures, more than 70,000 more votes than the signature threshold for ballot initiatives in Florida.

The measure cleared one of its first challenges to land on the 2024 ballot, receiving enough signatures to qualify for a court review of its language. This review is meant to ensure that none of the language in the cannabis legalization ballot misleads voters and is in violation of the state’s constitution.

Several prior attempts at placing recreational cannabis measures on the ballot have failed at this stage.

Attorney general Moody also took action against the cannabis legalization measure at this stage, filing a court brief that argued that the measure violated Florida’s constitutional rule of having a single subject in ballot measures and stating that she would flesh out her position in a future briefing. Moody also attempted to block a legalization measure based on the same argument in 2022, but a court threw out her file.

If the legalization measure is approved by voters, it would amend Florida’s constitution and allow existing medical marijuana companies to begin selling recreational cannabis to adults aged 21 years and older. The measure would also “allow but not require” that legislators take extra steps to approve and legalize additional recreational cannabis retailers in the state.

Adults aged 21 and older would be allowed to buy and own up to one ounce of cannabis with only a maximum of five grams being cannabis concentrate products. The ballot measure also includes provisions for the expungement of past cannabis offenses and would not allow home cultivation.

As the possibility of marijuana legalization becomes a reality in different states around the country, market opportunities will keep opening up for businesses such as Advanced Container Technologies Inc. (OTC: ACTX) as more growers come aboard the state-legal cannabis industry.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

More than 100 budtenders in Manitoba accept their first collective agreement

More than 100 budtenders in Manitoba accept their first collective agreement

Employees at a chain of retail stores in Manitoba have signed a collective agreement with the United Food and Commercial Workers (UFCW), highlighting concerns with safety rates of pay and what they say are unfair penalties. 

The new 30-month agreement was signed on June 14 and covers employees at ten The Joint locations in the province. The Joint also has stores in Saskatchewan and Alberta. 

The Union first received a province-wide certificate in June 2022 after workers contacted UFCW Local 832 about joining the union.

“I’m proud of our new members who stood up for their rights to join UFCW and worked together on not only organizing their workplace but also working with us to obtain the first collective agreement for Cannabis retail workers in the province of Manitoba”, stated UFCW Local 832 President, Jeff Traeger.

The union says the new 30-month collective agreement addresses numerous concerns that were raised during the organizing drive, such as safety concerns, rates of pay, and “unjust disciplines”.

The union held a meeting for members of The Joint on June 13.

“This is a fairly new industry. Since these workers have joined us, we have heard from numerous other Cannabis retail workers about joining our union. Many of them have been waiting to see what a collective agreement would provide them. We will continue to work on advocating for all Cannabis workers in Manitoba to ensure this industry has the proper protections these workers deserve.”

UFCW Local 832 represents over 19,000 Manitoban workers in food production, food distribution, warehousing, hospitality, security, personal care, assisted living, grocery retail and cannabis retail.

A representative with the Joint was not able to provide comment as of press time. This article will be updated when a comment is made available.

Unions and cannabis in Canada

Budtenders and cannabis employees in other provinces have also been unionizing, or seeking to do so. A union representing BC cannabis retail employees has slowly been gathering members since it became the first union to represent budtenders in Canada in 2020.

In August 2022, the BC General Employees Union launched a strike that shut down the province’s cannabis and alcohol distribution system, leaving cannabis stores with no access to new deliveries for weeks.

The SQDC, which manages cannabis sales in Quebec, has been dealing with an ongoing strike, which continues in 22 of their 90 branches. Although these branches are still open, they are operating at reduced hours and face picket line pressures. 

In June, members of a different union, the Confederation of National Trade Unions (CSN), voted to accept an agreement with the SQDC for increased wages, hours, and better working conditions.

The provincial organization is still negotiating with the Canadian Union of Public Employees (CUPE), which represents 28 of its 90 branches. In September, the Superior Court of Quebec issued an injunction to limit union “pressure tactics” against SQDC.

In 2020, a court ruled a BC cannabis company had unfairly penalized workers for trying to unionize. In September 2020, the union began organizing and soon applied to be certified for 17 employees at a Peachland, BC operation. 

Then, on October 5, the company laid off nine employees at the same Peachland operation, citing “the Company’s financial circumstances.”  The union argued these employees were laid off for seeking to unionize. The court agreed.

In 2016, UFCW tried to organize workers at a MedReleaf facility in Ontario, but the Ontario Labour Relations Board ruled the workers did not have the right to unionize. The union has appealed that ruling.


West Coast Premiere of Oaksterdam Documentary

West Coast Premiere of Oaksterdam Documentary

American Pot Story: Oaksterdam celebrates its West Coast premiere at the prestigious DANCES WITH FILMS Festival on June 29 at the historic TCL Chinese Theatre in the heart of Hollywood, Calif. 

The film revolves around Oaksterdam University (OU), the world’s first cannabis college, and tells the unknown origin story of the people who took monumental risks to make cannabis legalization possible. It celebrates the courageous heritage of the legacy industry and the movement that started at OU and would go on to impact the world. 

DWF Producing Partner and Documentary Programming Chair Jackie Tepper states, “American Pot Story: Oaksterdam encapsulates the unflinching spirt at the very core of the independent film scene, not only in the content of the movie, but in the movement that was created from it.  We champion that fighting spirit at DWF, and are proud to have programmed this important documentary about the current worldwide revolution in cannabis policy. ” 

The award-winning documentary, by critically-acclaimed filmmakers Dan Katzir and Ravit Markus, sheds light on the cannabis legalization movement through the lens of Oaksterdam University leaders. Katzir and Markus spent 10 years shadowing OU Founder Richard Lee and Executive Chancellor Dale Sky Jones as they fought to get the Prop 19 legalization measure on the ballot in California, then as they weathered a federal raid that threatened to shut them down. They captured their struggles and triumphs as they fought to bring this topic to the mainstream.

OU is located in the Bay Area of California, not far from the famous Emerald Triangle. It first opened its doors in 2007. The school has over 80,000 alumni worldwide and is the most recognized and trusted name in cannabis education.  “Our vision has always been revolutionary,” Jones says. “The industry has come so far, yet we have a long way to go federally. We look forward to continuing to be at the forefront of education, legal and public policy advocacy, social impact, and leadership.” 

FILM PREMIERE

Schedule: Thursday, June 29, 2023

Location: The historic  TCL Chinese Theatres

6:30 p.m. – Media Call

7 p.m. – Screening of American Pot Story: Oaksterdam

8:35 p.m. – Panel Discussion with Filmmakers & Dignitaries

9 p.m. – After-Party at the The Hollywood Roosevelt 

The Oaksterdam Nonprofit for Education (The ONE), a 501(c)(3), will produce the after-party sponsored by Incognito. All after-party ticket sales, donations, and sponsorships are tax-deductible. Proceeds fund scholarships for disadvantaged individuals and for those affected by marijuana Prohibition who are trying to gain meaningful employment in the legal cannabis industry.

About DANCES WITH FILMS:

DANCES WITH FILMS, heading into its 26th year, champions the unflinching spirit at the very core of the independent film scene. While the vast majority of film fests rely heavily on celebrity, DWF has relied on the innovation, talent, creativity, and sweat equity that revolutionized the entertainment industry. That reliance continues to prove successful, with alumni moving on to write, direct and produce celebrity-studded vehicles, star in blockbuster movies and television series, produce multi-million dollar films and create hit TV shows. 

[embedded content]

[embedded content]

New Study Shows How Psilocybin Can Help Treat Alcohol Use Disorders

Previous research has discovered that psilocybin can effectively treat substance-use disorders. Now, a new study has provided new insights into how psilocybin-assisted therapy works for individuals who are addicted to alcohol.

For their study, scientists at UC San Francisco, NYU and Fluence explored the therapeutic mechanisms that led to a considerable reduction in negative drinking behavior among 13 participants suffering from alcohol use disorders. Fluence is an education platform that specializes in the training and certification of psychedelic mental health therapists.

Before the trial, each participant reported on their relationship with alcohol. The majority of participants admitted to having used destructive coping mechanisms to manage uncomfortable situations throughout their childhoods and well into their adult lives. The researchers also observed that the participants experienced inner narratives including resentment toward those they were close to, guilt and excessive blame, which made them even more self-critical.

During the trial, each participant received a dose of psilocybin, which most said created emotions that had long been suppressed.

Months after the participants underwent psychedelic therapy, they were asked questions about their experiences after the trial. The participants revealed that psilocybin treatment assisted them in processing emotions linked to past painful events, in addition to promoting feelings of interconnectedness and states of self-awareness as well as self-compassion. In addition, the participants reported improvements in the quality of their relationships after the trial as well as new feelings of belonging.

In their report, the researchers noted that these findings supported the claims that psilocybin reduced self-critical and shame-based thought patterns and toned down alcohol cravings and affect regulation. The researchers added that their discovery also suggested that psychosocial therapies that integrated psychedelic treatment with training in self-compassion could help enhance the psychological outcomes of alcohol use disorder patients.

In their report, the authors highlighted common themes observed among the volunteers that could help inform future studies and therapeutic applications, especially now that more states are promoting regulated access to psychedelics and research into the substances.

For instance, Governor Jared Polis of Colorado signed a measure in May that would establish a regulatory framework for legal psychedelic substances. Additionally, regulators in Oregon recently approved a license for a psilocybin service center, the first of its kind in the country. This center will allow individuals to receive psychedelics in a facilitated and supervised environment.

The study’s findings were reported in the “Psychology of Addictive Behaviors” journal, by the American Psychological Association.

As more for-profit entities such as atai Life Sciences N.V. (NASDAQ: ATAI) publish studies demonstrating other therapeutic benefits of psychedelics, public interest in these substances is likely to grow. These therapies have potential to help millions of people who aren’t responding to existing treatments.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

More than 100 budtenders in Manitoba accept their first collective agreement

Senate Committee on Indigenous Peoples calls for jurisdiction over cannabis possession, sale, distribution in Canada

The Senate Committee on Indigenous Peoples calls for more control over cannabis rules within First Nations communities, says a report tabled today. 

The committee’s report is intended to inform the work of the ongoing legislative review of the Cannabis Act, which is expected to table their report in 2024. 

The report argues that the Cannabis Act has failed to recognize the argument made by many First Nations’ representatives in the lead-up to legalization in regard to a desire for jurisdictional authority around how cannabis is sold and distributed on First Nations land. In 2018, the committee called for delaying legalization until these issues were resolved.

The report concludes that this has effectively “shut out” First Nations’ participation in the cannabis industry in Canada. 

Among the report’s 13 recommendations is for legislation to amend the federal Cannabis Act to allow First Nations to regulate the possession, sale and distribution of cannabis on their lands. The committee also calls for increased funding for policing and enforcement of First Nations cannabis laws and additional funding and training for First Nations police services. 

The report also notes that only a small portion of First Nations-owned or affiliated cannabis businesses have received a federal commercial cannabis licence.

“It is disappointing to once again be forced to try to correct oversights that could have been prevented had the federal government listened to First Nations people from the beginning,” said Senator Brian Francis, Chair of the committee. “In the spirit of reconciliation, the government must promote, rather than hinder, the full and equal participation of our people and communities in the economy.”

The report also calls for more supports for First Nations communities with enforcement of their own cannabis rules and regulations. One example the report provides is from Edward Lennard Busch, of the First Nations Chiefs of Police Association, who told the committee that First Nations police services have noted that illicit dispensaries are operating on their territories.

Busch said that the fines issued to these stores were not sufficient deterrence, noting “It’s anywhere from a $1,000 to $5,000 fine. A lot of these dispensaries make that in a day. The majority of the dispensaries open the same day or the next day after we execute a search warrant on the premises.”

The report calls on the Government of Canada to ensure better funding is available to Indigenous communities for the policing and enforcement of band by-laws related to cannabis.

There are a handful of federally-licensed cannabis producers that are owned, at least in part, by members of First Nations communities. The federal government also maintains an Indigenous Navigator program to help First Nations-affiliated companies navigate the application process. 

While provincial governments control cannabis sales and distribution in their jurisdiction, several provincial governments have also been providing assistance to First Nations in their quest to operate cannabis stores.

The BC government has created special agreements with First Nations seeking to operate cannabis retail and production licences in the province, and Saskatchewan recently passed legislation giving First Nations the authority to licence cannabis retailers in their territories.  

Many Indigenous communities in Canada have disputed this interpretation, saying they have the right to manage cannabis as they see fit, either restricting it or regulating it. 

The Osoyoos Indian Band (OIB) first passed a moratorium against any cannabis stores in their community in 2019. The community then adopted their own Osoyoos Indian Band Cannabis Bylaw in 2020, citing section 35 of the Constitution Act, 1982, which recognizes and affirms the existing Aboriginal self-government and treaty rights of the Aboriginal peoples of Canada. 

The OIB’s corporate plan for 2018-2022 includes their intention to open “a new legal marijuana growing facility” and new marijuana retail outlets. The band licensed their first retailer in September 2020, Brewer’s Timix’w Wellness.

These approaches are not unique to BC. A First Nations community in New Brunswick put a moratorium on cannabis stores in their community in 2021.

Many First Nations community leaders argue for their own authority to manage cannabis sales and even production. Some legal experts and activists have also seen the potential to utilize the issues surrounding cannabis licensing to highlight overarching and historical jurisdictional challenges to federal and provincial laws

One Indigenous man in BC is suing the government over a raid of his store in 2020. A Mi’kmaw band councillor from Millbrook First Nation in Nova Scotia, arrested in a 2020 police raid of Indigenous cannabis dispensaries, is mounting a constitutional defence arguing his right to sell cannabis on First Nations land is constitutionally protected.

Not all First Nations are opposed to working with federal and provincial regulations. Several Indigenous businesses and governments across Canada have opted to work within these frameworks, as well as crafting their own rules to work in coordination with federal and/or provincial governments.

In 2022, a group of cannabis retailers in BC sued the government for what they say is a lack of enforcement of the province’s own cannabis regulations, highlighting unregulated cannabis stores, many of which operate on First Nations land in BC’s interior. The Tseshaht First Nation Elected Chief and Council on Vancouver Island, which is home to a First Nations-owned, provincially-licensed retail store, has called on the BC government to “take swift action on provincially unlicensed stores within Tseshaht’s territory”.

Representatives from the Senate Committee on Indigenous Peoples Committee spoke to media today on CPAC. Deputy chair of the committee, Senator David Arnot, said he is disappointed that the government is failing to live up to its promises of reconciliation.

“Once again, a government that says it is committed to building a renewed relationship with Indigenous Peoples based on the recognition of rights, respect, and partnership has failed to live up to its promise. Once again, Indigenous Peoples have been excluded from participation in the economic prosperity of the country. And once again, little regard has been given to how our lives have been impacted.”


On the Outside Looking In: The Implementation of the Cannabis Act and its effects on Indigenous Peoples 32 List of Recommendations 

Recommendation 1 That the Expert Panel engage in substantive consultations and propose solutions to the problems raised by Indigenous peoples related to legal jurisdiction, enforcement, equity and inclusion in the industry, and mental health and substance abuse and that funding be made available to Indigenous peoples during this process. 

Recommendation 2 That the Minister of Health introduce legislation in Parliament to amend the Cannabis Act to permit First Nations to regulate the possession, sale and distribution of cannabis on their lands.

Recommendation 3 That the Government of Canada convene a meeting with First Nations, federal, provincial and territorial governments in the spirit of cooperation and collaboration to solve jurisdictional challenges to enable First Nations to exercise their rightful place in the cannabis marketplace.

Recommendation 4 That the Government of Canada, as it develops legislation related to First Nation policing, in collaboration with the provinces and the territories and First Nations governments, establish legislative mechanisms for the enforcement of band by-laws and other laws related to cannabis by all police services and to ensure that related offences can be investigated and prosecuted effectively. 

Recommendation 5 That the Government of Canada furthermore ensure adequate funding is available to Indigenous communities for the policing and enforcement of band by-laws related to cannabis. 

Recommendation 6 That the Royal Canadian Mounted Police provide dedicated space for First Nations police services to undertake Drug Recognition Expert Training and that Public Safety Canada provide additional funding to First Nations policing to support this work. 

Recommendation 7 That Finance Canada work with First Nations to identify options for the development of an excise tax-sharing framework as part of its discussions on the fuel, alcohol, cannabis and tobacco tax. 

Recommendation 8 That Finance Canada and Indigenous Services Canada work with First Nations communities to identify options for the establishment of a First Nation-led agency to support First Nations participation in the cannabis market. 

Recommendation 9 That Health Canada and the Canada Revenue Agency work with Indigenous peoples and communities to undertake a review of their application processes for all cannabis-related licences and report the findings back to the committee by December 2023. 

Recommendation 10 That Indigenous Services Canada cover cannabis for medical purposes under the Non-Insured Health Benefits Program. 

Recommendation 11 That the Government of Canada work with cannabis producers to ensure the product is available for medical coverage under Indigenous Services Canada’s Non-Insured Health Benefits. 

Recommendation 12 That Health Canada and Indigenous Services Canada work with Indigenous peoples and communities to establish and fund a research strategy on cannabis and its effects on Indigenous peoples and communities. 

Recommendation 13 That Health Canada and Indigenous Services Canada provide funding for the development and update of Indigenous-led public health information on cannabis.


Aurora Cannabis on the hunt for savings again, says Bevo deal boosted Q3 revenue

By Tara Deschamps

Aurora Cannabis Inc. is on the hunt for more savings after wrapping a transformation plan that delivered at least $400 million in savings over the last three years.

The Edmonton-based cannabis producer said Wednesday that it wants to uncover another $40 million in savings by the end of next March, which marks the end of the company’s fiscal year.

“This incremental reduction puts us squarely on the path to reach our next financial milestone, which is positive free cash flow,” Miguel Martin announced on a call with analysts.

Advertisement

Free cash flow is an indicator of a company’s financial performance because it encapsulates money a company makes after accounting for expenses that support operations.

Profitability has been difficult across Canada’s cannabis industry, where a lack of demand, strict regulations and the strength of the illicit market have hampered the financial performance of most businesses. Many, including Aurora and its rivals, have resorted to layoffs, facility closures and intense evaluations of their product mix to weather such conditions.

Aurora, which has been pursuing sales in several European markets, recently decided to close its Nordic production facility in Denmark and rely on its Canadian facilities to supply the market.

The Canadian facilities have a lower per unit costs, higher quality and a much more reliable supply, chief financial officer Glen Ibbott said on the same call as Martin.

“We believe this change, in addition to reduced costs, will allow us to compete even more effectively in the growing European market, where we already have a substantial leadership position,” he said.

Across the entire business this fiscal year, he said Aurora was aiming to take away at least $5 million quarterly as less efficient operations are eliminated and at least another $5 million from cost reduction initiatives.

He also expects the company to save about $2 million per interest quarter in interest as it pays off the remainder of its convertible debt, which stands at about $80 million. Ibbot said Aurora intends to pay the debt off at the end of this fiscal year.

His remarks came as the company revealed its adjusted earnings before interest, taxes, depreciation and amortization totalled $310,000 for the quarter ended March 31 compared with a loss of $10 million a year earlier.

Net revenue totalled $64.0 million for what was the company’s third quarter, up from $50.4 million in the same quarter last year.

Aurora says medical cannabis revenue for the quarter totalled $38.0 million, down from $39.4 million, due to limited supply of high-demand products in certain European markets as the company had production issues at its Nordic production facility.

Consumer cannabis revenue amounted to $14.5 million, up from $10.3 million in the same quarter last year.

One of the company’s brights spots was Bevo Agtech Inc., a supplier of vegetable seedlings and flowers, which it acquired last year.

Aurora earned $10.8 million in plant propagation revenue from Bevo in the quarter, which Martin attributed to the seasonality of the business.

Bevo revenues, he explained, are highest in the late winter and spring months.

420 with CNW — Supreme Court Gives Florida AG Extra Fortnight to File Cannabis Challenge

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) May Announcements Show Resolve to Continue Supporting R&D ‘Lifeblood’

image
  • In May, Lexaria made a number of positive announcements related to its R&D initiatives
  • In addition to holding its 2023 Annual Meeting, the company completed dosing for its human clinical nicotine study, NIC-H22-1
  • Lexaria also reported 900% improvements in delivery of DehydraTECH(TM) processed estrogen into blood plasma in an animal study
  • In a human hypertension study, the company announced that its DehydraTECH-CBD formulation resulted in significant reductions in the blood plasma levels of pro-inflammatory biomarkers (IL 8, 10, and 18)
  • These biomarkers are linked to cardiovascular disease (“CVD”) and many other conditions, such as asthma, lung diseases, chronic kidney disease, fatty liver disease, Type 1 and 2 diabetes, obesity, and rheumatoid arthritis

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, held its 2023 Annual Meeting on the 9th of May, with shareholders voting on several agenda items, including the election of directors, appointment of auditors, approval of the stock option pricing, approval of the amendment to the maxim number of shares issuable pursuant to the Incentive Equity Plan, and approval of the addition of an evergreen formula to the Incentive Equity Plan. All items put to the vote were approved by the majority, setting the stage for what would become a month of even more positives, particularly around the company’s research and development (“R&D”) initiatives.

“If you’ve been following Lexaria for any period of time, you know that applied R&D is our lifeblood. It helps us establish areas of investigation for commercial pursuits, reduces risks of the unknown for both commercial and regulatory goals, and more,” wrote Lexaria CEO Chris Bunka in the January 2023 annual letter (https://cnw.fm/o1Ypu).

A look at the company’s announcements throughout May shows its unwavering resolve to support its lifeblood and, in the process, gain additional knowledge and understanding of the limitations and capabilities of its patented DehydraTECH(TM) technology. The company started the month off with the announcement that it had completed dosing in its human clinical nicotine study, NIC-H22-1.

With data showing that cigarette smoking claims the lives of more than 7 million people per year globally, Lexaria conducted the study as part of its efforts to validate its reduced-risk technology, which is poised to potentially provide tobacco smokers with a safer and faster-acting source of purified nicotine that delivers nicotine into blood plasma faster, potentially satisfying cravings more quickly. The study evaluated the capabilities of the company’s DehydraTECH-processed oral nicotine formulation by comparing it with the performance of other commercially available oral nicotine pouches sold under the On! and Zyn brands. Lexaria will provide further updates and any relevant material findings as they become available (https://cnw.fm/5YIKF).

Lexaria also reported the completion of its animal study HOR-A22-1, demonstrating its DehydraTECH(TM) platform technology significantly enhanced the oral delivery of estradiol, a type of estrogen hormone that is used in therapeutic products in women’s health sector (https://cnw.fm/wwDVX). Performed in 20 female Sprague-Dawley rats, the study compared a DehydraTECH-estradiol formulation to a generic estradiol composition.

The study aimed to evaluate the ability of DehydraTECH to enhance the delivery properties of the orally administered hormone using parameters such as Cmax, the maximum concentration in the bloodstream, and area under the curve (“AUC”), a measure that gives insight into the total delivery of estradiol over time and the extent of exposure to estrone. (Estrone is a second type of estrogen that is reversibly manufactured from estradiol in tissues found in the mammary gland, uterus, and liver.)

The animal study HOR-A22-1 found that the DehydraTECH-estradiol formulation resulted in a Cmax about 900% higher than the control formulation’s. Additionally, the AUC readings for estradiol and estrone when the DehydraTECH-processed composition was used were 1,500% and 12,500% higher, respectively, than when the control was used.

In other R&D, Lexaria announced additional findings from its human clinical study HYPER-H21-4, completed last year. The hypertension study sought to evaluate DehydraTECH-processed cannabidiol (“CBD”) as a potential antihypertensive medication and already achieved primary efficacy and safety objectives. According to the company, the study also demonstrated significant reductions in several pro-inflammatory biomarkers – interleukin (“IL”) 8, 10, and 18 – known to be linked to cardiovascular disease (“CVD”) and many other conditions such as asthma, lung diseases, chronic kidney disease, fatty liver disease, type 1 and 2 diabetes, obesity, and rheumatoid arthritis.

More specifically, after five weeks of treatment, the DehydraTECH-CBD formulation resulted in a 19%, 27%, and 43% reduction in the blood plasma levels of IL 8, 10, and 18, respectively. “There is some pre-clinical evidence for the anti-inflammatory actions of CBD, but this is likely the most convincing evidence in humans that I have ever seen,” Dr. Philip Ainslie, Cardiovascular Advisor to Lexaria and Lead Investigator of the study, said of the results.

In non-R&D-related news, the company reported the closing of its public offering, which generated approximately $2.0 million in gross proceeds (https://cnw.fm/1EL5N).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.